FDA Breakthrough for Pancreatic Cancer RAS Inhibitors
The U.S. Food and Drug Administration (FDA) has granted breakthrough designations targeting mutated RAS proteins in pancreatic ductal adenocarcinoma. This regulatory milestone shifts decades of oncological dogma, providing new molecular … Read More